GlobeNewswire by notified

Align Technology Launches New iTero Element 5D Imaging System for Comprehensive Preventative and Restorative Oral Care at IDS

Share

SAN JOSE, Calif., Feb. 18, 2019 (GLOBE NEWSWIRE) --

  • First intraoral scanner with near-infrared imaging (NIRI) technology that scans the internal structure of a tooth (enamel & dentin) in real time1.
  • First integrated dental imaging system that simultaneously records 3D, intra-oral color and NIRI, and enables comparison over time using iTero® TimeLapse1.
  • NIRI technology of the iTero Element® 5D system aids in detection and monitoring of interproximal caries lesions above the gingiva without using harmful radiation1.
  • New web-based interface MyiTero.com complements visualization of the iTero Element 5D system.
  • Limited-release direct doctor-lab workflow automatically sends scan to lab of choice.

Align Technology, Inc. (NASDAQ: ALGN) today announced that it is launching the iTero Element 5D Imaging System, which provides a new comprehensive approach to clinical applications, workflows and user experience that expands the suite of existing high-precision, full-color imaging and fast scan times of the iTero Element portfolio. The entire iTero product family, including the iTero Element 5D Imaging System, will be showcased at the 38th International Dental Show (IDS) in Cologne Germany, which runs March 12 – 16, 2019.

iTero Element 5D Imaging System: more than just a scanner
In addition to offering all of the features and functionality that doctors have come to expect and rely on with the iTero Element 2 scanner, the iTero Element 5D scanner is the first integrated dental imaging system that simultaneously records 3D, intra-oral color and NIRI images and enables comparison over time using iTero TimeLapse1. Integrated 3D,  intra-oral color and NIRI technology of the iTero Element 5D Imaging System aids in detection and monitoring of interproximal caries lesions above the gingiva without using harmful radiation1. With one full arch scan, in as little as 60 seconds, the iTero Element 5D Imaging System provides doctors with powerful visualization capabilities, including the following:

  • 3D impressions for restorative and orthodontic work
  • Analysis instruments, such as the occlusal clearance tool2
  • NIRI imagery
  • Intraoral camera imagery
  • iTero TimeLapse technology
  • Invisalign® Outcome Simulator2
  • Invisalign Progress Assessment2

“The iTero Element 5D Imaging System combines the cutting-edge technology of the iTero Element portfolio of intraoral scanners, with advanced integrated imaging features, such as NIRI, which aids in interproximal caries detection and clear intra-oral images with the built-in intraoral camera,” said Zelko Relic, Align Technology, CTO and senior vice president, global research and development. “With this new imaging system, doctors can efficiently and effectively scan every patient at every visit and visualize treatment options together that result in more informed decisions for optimum oral care.”  

“Diagnosing carious lesions or ‘cavities,’ especially ones that are interproximal or between teeth, can be hampered by numerous factors, including variations in tooth shape and alignment, traditional X-ray film limitations that include variability in exposure levels, poor angulations in image capture or overlapping contacts in the image, and more,” said Dr. Mitra Derakhshan, Align Technology, vice president, global clinical. “The iTero Element 5D Imaging System aids doctors in detecting and monitoring the progression of interproximal cavities above the gingiva without harmful radiation, thereby helping to ensure that their patients receive even better care.”

Dr. Tim Nolting, a general practioner from Freudenberg, Germany, who was part of the iTero Element 5D Imaging System limited market release said, “The iTero Element 5D scanner has been a real game changer and given me a totally new reason to incorporate digital technology in my practice. Patients value minimally invasive treatment and radiation free diagnosis. With the addition of the iTero Element 5D System in my diagnostic tool box, diagnosis itself is easier to make and since I can show my patients what I am seeing, they understand the situation better and in turn accept the proposed treatment.”

“The pace of innovation at Align continues to accelerate, and the Element 5D Imaging System expands the iTero portfolio by offering dental professionals a wide range of powerful scanning technology at every price point,” said Yuval Shaked, Align Technology, senior vice president and managing director, iTero Scanners and Services.  “As the leader in digital scanning technology with over 20 years of experience, we understand the nature of platform evolution and how important it is to support our doctors and provide an upgrade path that protects their investment. With iTero Element 5D Imaging System, dental professionals now have the ability to invest in more than an intraoral scanner, thus maximizing opportunities within their dental practice. The platform nature of iTero Element 5D System makes it easy for dental professionals to upgrade to the latest digital technology when they are ready.”

MyiTero.com: New web-based interface that frees the scanner for scanning
Align Technology now also offers a web-based platform called MyiTero.com that complements the comprehensive visualization of the iTero Element 5D Imaging System and can be used to set up prescription before the appointment and review scans with the patient on multiple devices, giving the practice the flexibility to assist more patients with this cutting-edge technology. MyiTero.com frees up the scanner so the practice can really maximize the utilization of their scanner and the overall investment in the technology.

Direct doctor-lab workflow in limited release: Workflow options that fit doctor-lab needs
Align Technology is continuing to streamline workflows for dentists and labs with the addition of direct doctor-lab workflow. The new workflow will allow the scan to be automatically sent to the doctor’s lab of choice and the doctor can engage with the lab through the MyiTero.com account to determine if the scan is acceptable or if additional information is needed. This workflow will continue to be supported with on-demand services like iTero modeling and iTero customer milled models, both unique to iTero Element scanners, that the labs have come to count on. Direct doctor-lab workflow is currently in limited market testing in North America and Europe.

1 Data on file at Align Technology, as of December 4, 2018.
2 Comes standard in all iTero Element scanners.

The iTero Element 5D Imaging System is commercially available now in Canada, European Union countries accepting CE-Marking (excluding Greece), Switzerland, Norway, Australia, New Zealand, Hong Kong and Thailand. The iTero Element 5D Imaging System is not yet available in the United States or Latin America.

Information about the iTero Element 5D Imaging System can be found at http://www.itero.com/en.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align's products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com.

Align Technology                                                                                        
Karina Ludz                                                                                           
(316) 21143420                                                                                      
kludz@aligntech.com                                                                           

Zeno Group
Sarah Johnson
(828) 551-4201
sarah.johnson@zenogroup.com

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/b06170ee-c19b-4093-b5c1-fcbc8aae9455

http://www.globenewswire.com/NewsRoom/AttachmentNg/76a84de2-12fd-4978-8699-7a7a07d5a706

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye